sodium 2-naphthylmethanesulfonate

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: sodium 2-naphthylmethanesulfonate
• 英文别名: Sodium naphthalen-2-ylmethane sulfonate；sodium;naphthalen-2-ylmethanesulfonate
• 化学式: C₁₁H₉O₃S*Na
• 分子量: 244.246
• InChiKey: JNDHKCGKSMDFNV-UHFFFAOYSA-M

计算性质

• 辛醇/水分配系数(LogP)：
  -1.11
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  65.6
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  sodium 2-naphthylmethanesulfonate 在 氯化亚砜 、 N,N-二甲基甲酰胺 作用下， 以 二氯甲烷 为溶剂， 反应 1.5h， 生成 2-萘甲烷磺酰氯
  参考文献：
  名称：

  吲哚胞质磷脂酶A2α抑制剂：4- {3- [5-氯-2-（2-{[（3,4-二氯苄基）磺酰基]氨基}乙基）-1-（）的发现以及体内和体外表征二苯甲基）-1H-吲哚-3-基]丙基}苯甲酸，依非拉地。

  摘要：

  本文描述了一类吲哚cPLA 2α抑制剂的优化。突出了C 3处取代基的重要性和苯基甲烷磺酰胺区的取代方式。这些区域的优化导致发现111（efipladib）和121（WAY-196025），在各种分离的酶测定，基于细胞的测定以及大鼠和人类中，它们被证明是有效的cPLA 2α选择性抑制剂。全血检测。这些化合物的结合已使用等温滴定热法进一步检查。最后，当在多种急性和慢性前列腺素和白三烯依赖性的体内模型中口服给药时，这些化合物显示出功效。

  DOI：

  10.1021/jm701467e
• 作为产物：
  描述：

  2-甲基萘 在 N-溴代丁二酰亚胺(NBS) 、 sodium sulfite 作用下， 以 四氯化碳 、 水 、 丙酮 为溶剂， 反应 16.0h， 生成 sodium 2-naphthylmethanesulfonate
  参考文献：
  名称：

  Synthesis of novel dihydronaphthothiazine S,S -dioxides by intramolecular sulfonylamidomethylation of 2-naphthylmethanesulfonamides using Amberlyst XN-1010

  摘要：

  We describe herein an efficient synthetic method for novel dihydronaphthothiazines S,S-dioxides by aromatic intramolecular sulfonylamidomethylation of 2-naphthylmethanesulfonamides with s-trioxane using Amberlyst XN-1010 as acid heterogeneous catalyst. Cyclization of the formed sulfonyliminium ion occurred with high regioselectivity and in excellent yields. (C) 2015 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetlet.2015.11.042

文献信息

• COMPOUNDS CAPABLE OF INHIBITING VOLTAGE GATED CALCIUM ION CHANNEL, AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME
  申请人：KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY

  公开号：US20150329533A1

  公开（公告）日：2015-11-19

  Disclosed herein are an N-(pyrazolylmethyl)arylsulfonamide derivative useful as a calcium ion channel blocker, a pharmaceutically acceptable salt thereof, and the medicinal use thereof as a therapeutic agent using its calcium ion channel blocking effect.

  本文披露了一种N-(吡唑甲基)芳基磺酰胺衍生物，可用作钙离子通道阻滞剂，其药用盐，以及利用其钙离子通道阻滞效应作为治疗剂的药用。
• Indole Cytosolic Phospholipase A₂ α Inhibitors: Discovery and in Vitro and in Vivo Characterization of 4-{3-[5-Chloro-2-(2-{[(3,4-dichlorobenzyl)sulfonyl]amino}ethyl)-1-(diphenylmethyl)-1<i>H</i>-indol-3-yl]propyl}benzoic Acid, Efipladib
  作者：John C. McKew、Katherine L. Lee、Marina W. H. Shen、Paresh Thakker、Megan A. Foley、Mark L. Behnke、Baihua Hu、Fuk-Wah Sum、Steve Tam、Yonghan Hu、Lihren Chen、Steven J. Kirincich、Ronald Michalak、Jennifer Thomason、Manus Ipek、Kun Wu、Lane Wooder、Manjunath K. Ramarao、Elizabeth A. Murphy、Debra G. Goodwin、Leo Albert、Xin Xu、Frances Donahue、M. Sherry Ku、James Keith、Cheryl L. Nickerson-Nutter、William M. Abraham、Cara Williams、Martin Hegen、James D. Clark

  DOI：10.1021/jm701467e

  日期：2008.6.1

  The optimization of a class of indole cPLA 2 alpha inhibitors is described herein. The importance of the substituent at C3 and the substitution pattern of the phenylmethane sulfonamide region are highlighted. Optimization of these regions led to the discovery of 111 (efipladib) and 121 (WAY-196025), which are shown to be potent, selective inhibitors of cPLA 2 alpha in a variety of isolated enzyme assays

  本文描述了一类吲哚cPLA 2α抑制剂的优化。突出了C 3处取代基的重要性和苯基甲烷磺酰胺区的取代方式。这些区域的优化导致发现111（efipladib）和121（WAY-196025），在各种分离的酶测定，基于细胞的测定以及大鼠和人类中，它们被证明是有效的cPLA 2α选择性抑制剂。全血检测。这些化合物的结合已使用等温滴定热法进一步检查。最后，当在多种急性和慢性前列腺素和白三烯依赖性的体内模型中口服给药时，这些化合物显示出功效。
• (Hetero) Bicyclymethanesulfonylamino-substituted hydroxamic acid derivatives
  申请人：——

  公开号：US20030199571A1

  公开（公告）日：2003-10-23

  Compounds of formula (I) wherein R is hydrogen, alkyl alkenyl, alkynyl, aryl, heteroaryl or heterocyclyl; and R 1 is bicyclyl or heterobicyclyl; are useful in the treatment and prophylaxis of conditions mediated by s-CD23 or TNF.

  式（I）中的化合物，其中R是氢，烷基烯基，炔基，芳基，杂芳基或杂环烷基；R1是双环烷基或杂双环烷基；在通过s-CD23或TNF介导的疾病的治疗和预防中是有用的。
• Designing Anti-inflammatory Drugs from Parasitic Worms: A Synthetic Small Molecule Analogue of the <i>Acanthocheilonema viteae</i> Product ES-62 Prevents Development of Collagen-Induced Arthritis
  作者：Lamyaa Al-Riyami、Miguel A. Pineda、Justyna Rzepecka、Judith K. Huggan、Abedawn I. Khalaf、Colin J. Suckling、Fraser J. Scott、David T. Rodgers、Margaret M. Harnett、William Harnett

  DOI：10.1021/jm401251p

  日期：2013.12.27

  In spite of increasing evidence that parasitic worms may protect humans from developing allergic and autoimmune diseases and the continuing identification of defined helminth-derived immunomodulatory molecules, to date no new anti-inflammatory drugs have been developed from these organisms. We have approached this matter in a novel manner by synthesizing a library of drug-like small molecules based upon phosphorylcholine, the active moiety of the anti-inflammatory Acanthocheilonema viteae product, ES-62, which as an immunogenic protein is unsuitable for use as a drug. Following preliminary in vitro screening for inhibitory effects responses, a sulfone-containing phosphorylcholine analogue (11a) was selected for testing in collagen-induced arthritis (CIA). Testing revealed that 11a was as effective as ES-62 in protecting DBA/1 mice from developing CIA and mirrored its mechanism of action in downregulating the TLR/IL-1R transducer, MyD88. 11a is thus a novel prototype for anti-inflammatory drug development. on relevant macrophage cytokine an in vivo model of inflammation,
• Novel phosphate mimetics for the design of non-peptidyl inhibitors of protein tyrosine phosphatases
  作者：Christopher C. Kotoris、Mei-Jin Chen、Scott D. Taylor

  DOI：10.1016/s0960-894x(98)00598-8

  日期：1998.11

  Benzylic alpha,alpha-difluorosulfonates, alpha,alpha-dinuorotetrazoles, and alpha,alpha-difluorocarboxylates of type 5 and 6 were synthesized and examined as potential phosphate biosteres for PTP1B inhibition. The alpha,alpha-difluorosulfonates and alpha,alpha-difluorotetrazoles were found to be more effective inhibitors than the analogous compounds bearing the fluoromalonyl group, a phosphate biostere currently being used for PTP inhibition. (C) 1998 Elsevier Science Ltd. All rights reserved.